MAFLD enhances clinical practice for liver disease in the Asia-Pacific region

키워드

참고문헌 (134)

1. Sarin SK, "Liver diseases in the Asia-Pacific region : a Lancet Gastroenterology & Hepatology Commission", Lancet Gastroenterol Hepatol, 5, pp.167~228 (2020)
2. 강성희, "KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(3), pp.363~401 (2021), 대한간학회
3. Tampi RP, "Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia : data from Hong Kong", Hepatol Res, 50, pp.1024~1031 (2020)
4. Terai S, "Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease(NAFLD)and nonalcoholic steatohepatitis(NASH)in the Japan medical data vision database", J Gastroenterol, 56, pp.274~284 (2021)
5. Golabi P, "Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa : data from global burden of disease 2009-2019", J Hepatol, 75, pp.795~809 (2021)
6. Wong MCS, "The changing epidemiology of liver diseases in the Asia-Pacific region", Nat Rev Gastroenterol Hepatol, 16, pp.57~73 (2019)
7. Chang KC, "Universal infant hepatitis B virus(HBV)vaccination for 35 years : moving toward the eradication of HBV", J Infect Dis, 225, pp.431~435 (2022)
8. Kim GA, "HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B : clinical outcomes and durability", Gut, 63, pp.1325~1332 (2014)
9. Busch MP, "Prevention of transfusion-transmitted infections", Blood, 133, pp.1854~1864 (2019)
10. Ji F, "Systematic review with meta-analysis : effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia", Aliment Pharmacol Ther, 47, pp.550~562 (2018)
11. "Hepatitis C"[URL]
12. Powell EE, "Non-alcoholic fatty liver disease", Lancet, 397, pp.2212~2224 (2021)
13. Estes C, "Modelling NAFLD disease burden in four Asian regions-2019-2030", Aliment Pharmacol Ther, 51, pp.801~811 (2020)
14. Takuma Nakatsuka, "Changing clinical management of NAFLD in Asia", Liver International, 42(9), pp.1955~1968 (2021), Wiley[DOI]
15. Zhang X, "Increasing prevalence of NAFLD", NASH among children, adolescents and young adults from 1990 to 2017 : a population-based observational study, 2021, pp.11, e042843~
16. Adams LA, "Nonalcoholic fatty liver disease burden : Australia, 2019-2030", J Gastroenterol Hepatol, 35, pp.1628~1635 (2020)
17. Roberts SK, "Prevalence of non-alcoholic fatty liver disease in regional Victoria : a prospective population-based study", Med J Aust, 215, pp.77~82 (2021)
18. Wong GL, "How many deaths are caused by non-alcoholic fatty liver disease in the Asia-Pacific region?", Lancet Gastroenterol Hepatol, 5, pp.103~105 (2020)
19. Viganò L, "Liver resection for hepatocellular carcinoma in patients with metabolic syndrome : a multicenter matched analysis with HCV-related HCC", J Hepatol, 63, pp.93~101 (2015)
20. Pang Y, "Diabetes, plasma glucose, and incidence of fatty liver, cirrhosis, and liver cancer : a prospective study of 0. 5 million people", Hepatology, 68, pp.1308~1318 (2018)
21. Nderitu P, "The association between individual metabolic syndrome components, primary liver cancer and cirrhosis : a study in the Swedish AMORIS cohort", Int J Cancer, 141, pp.1148~1160 (2017)
22. Kim H, "Metabolic spectrum of liver failure in type 2 diabetes and obesity : from NAFLD to NASH to HCC", Int J Mol Sci, 22, pp.4495~ (2021)
23. Ye Q, "Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 5, pp.739~752 (2020)
24. Kim D, "Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis", J Gastroenterol, 55, pp.330~341 (2020)
25. Kawaguchi T, "Is metabolic syndrome responsible for the progression from NAFLD to NASH in non-obese patients?", J Gastroenterol, 55, pp.363~364 (2020)
26. Zheng Q, "Systematic review with meta-analysis : prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B", Aliment Pharmacol Ther, 54, pp.1100~1109 (2021)
27. Fernandez-Fuertes M, "Similar prevalence of hepatic steatosis among patients with chronic hepatitis C with and without HIV coinfection", Sci Rep, 10, pp.6736~ (2020)
28. Yamada S, "Serum albumin level is a notable profiling factor for non-B, non-C hepatitis virus-related hepatocellular carcinoma : a data-mining analysis", Hepatol Res, 44, pp.837~845 (2014)
29. Kudo M, "Report of the 21st nationwide follow-up survey of primary liver cancer in Japan(2010-2011)", Hepatol Res, 51, pp.355~405 (2021)
30. Tateishi R, "A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan : 2011-2015 update", J Gastroenterol, 54, pp.367~376 (2019)
31. Siriwardana RC, "Association of serum ferritin with diabetes and alcohol in patients with non-viral liver diseaserelated hepatocellular carcinoma", Liver Cancer, 6, pp.307~312 (2017)
32. Barber SL, "Aging and universal health coverage : implications for the Asia Pacific region", Health Syst Reform, 3, pp.154~158 (2017)
33. McPake B, "Addressing the needs of an aging population in the health system : the australian case", Health Syst Reform, 3, pp.236~247 (2017)
34. Shiha G, "Redefining fatty liver disease : an international patient perspective", Lancet Gastroenterol Hepatol, 6, pp.73~79 (2021)
35. Fouad Y, "Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists", J Hepatol, 74, pp.1254~1256 (2021)
36. Eslam M, "A new definition for metabolic dysfunctionassociated fatty liver disease : an international expert consensus statement", J Hepatol, 73, pp.202~209 (2020)
37. Eslam M, "MAFLD : a consensus-driven proposed nomenclature for metabolic associated fatty liver disease", Gastroenterology, 158, pp.1999~2014 (2020)
38. Lee H, "Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk : a nationwide cohort study", Clin Gastroenterol Hepatol, 19, pp.2138~2147 (2021)
39. Fan J, "Prevalence and risk factors of metabolic associated fatty liver disease in the contemporary South China population", Nutr Metab(Lond), 18, pp.82~ (2021)
40. Yamamura S, "MAFLD identifies patients with significant hepatic fibrosis better than NAFLD", Liver Int, 40, pp.3018~3030 (2020)
41. Tsutsumi T, "MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD : generalized estimating equation approach", Hepatol Res, 51, pp.1115~1128 (2021)
42. Fukunaga S, "Non-obese MAFLD is associated with colorectal adenoma in health check examinees : a multicenter retrospective study", Int J Mol Sci, 22, pp.5462~ (2021)
43. Sun DQ, "MAFLD and risk of CKD", Metabolism, 115, pp.154433~ (2021)
44. van Kleef LA, "Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness : the Rotterdam study", Hepatology, 75, pp.419~429 (2022)
45. Wang X, "Metabolic dysfunction-associated fatty liver disease and mortality among Chinese adults : a prospective cohort study", J Clin Endocrinol Metab, 107, pp.e745~e755 (2022)
46. Wong VW, "Prognosis of MAFLD vs. NAFLD and implications for a nomenclature change", J Hepatol, 75, pp.1267~1270 (2021)
47. Qi Huang, "NAFLD or MAFLD: Which Has Closer Association With All-Cause and Cause-Specific Mortality?—Results From NHANES III", Frontiers in Medicine, 8 (2021), Frontiers Media SA[DOI]
48. Kim D, "Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States", J Hepatol, 75, pp.1284~1291 (2021)
49. Seong Hee Kang, "From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?", Clinical and Molecular Hepatology, 27(2), pp.257~269 (2021), 대한간학회[DOI]
50. Takumi Kawaguchi, "MAFLD: Renovation of clinical practice and disease awareness of fatty liver", Hepatology Research, 52(5), pp.422~432 (2021), Wiley[DOI]
51. Hirose S, "Nineteen-year prognosis in Japanese patients with biopsyproven nonalcoholic fatty liver disease : lean versus overweight patients", PLoS One, 15, pp.e0241770~ (2020)
52. Iritani S, "Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease", BMC Gastroenterol, 20, pp.368~ (2020)
53. Ito T, "The epidemiology of NAFLD and lean NAFLD in Japan : a metaanalysis with individual and forecasting analysis, 1995-2040", Hepatol Int, 15, pp.366~379 (2021)
54. Kim Yuna, "Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease", Gut and Liver, 16(2), pp.290~299 (2022), 거트앤리버 소화기연관학회협의회[DOI]
55. Omar T. Ahmed, "Natural History of Nonalcoholic Fatty Liver Disease With Normal Body Mass Index: A Population-Based Study", Clinical Gastroenterology and Hepatology, 20(6), pp.1374~1381.e6 (2022), Elsevier BV[DOI]
56. Younes R, "Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean : time for reappraisal of BMI-driven approach?", Gut, 71, pp.382~390 (2022)
57. Rahman MM, "Prevalence, risk factors and metabolic profile of the nonobese and obese non-alcoholic fatty liver disease in a rural community of South Asia", BMJ Open Gastroenterol, 7, pp.e000535~ (2020)
58. Semmler G, "Nonalcoholic fatty liver disease in lean subjects : associations with metabolic dysregulation and cardiovascular risk-a single-center cross-sectional study", Clin Transl Gastroenterol, 12, pp.e00326~ (2021)
59. Francque S, "NAFLD in lean individuals : not a benign disease", Gut, 71, pp.234~236 (2022)
60. Huiyul Park, "Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease", Gut, 71(5), pp.1035~1036 (2021), BMJ[DOI]
61. Wong VW, "Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease", J Hepatol, 69, pp.1349~1356 (2018)
62. Hamurcu Varol P, "Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients", Eur J Gastroenterol Hepatol, 32, pp.1352~1357 (2020)
63. Cheng YM, "The metabolic profiles and body composition of lean metabolic associated fatty liver disease", Hepatol Int, 15, pp.405~412 (2021)
64. Ciardullo S, "Prevalence of liver steatosis and fibrosis detected by transient elastography in adolescents in the 2017-2018 national health and nutrition examination survey", Clin Gastroenterol Hepatol, 19, pp.384~390 (2021)
65. Won Sohn, "Liver Fibrosis in Asians With Metabolic Dysfunction–Associated Fatty Liver Disease", Clinical Gastroenterology and Hepatology, 20(5), pp.e1135~e1148 (2022), Elsevier BV[DOI]
66. Liu Z, "The health impact of MAFLD, a novel disease cluster of NAFLD, is amplified by the integrated effect of fatty liver disease-related genetic variants", Clin Gastroenterol Hepatol, 20, pp.e855~e875 (2022)
67. Lin YP, "Impact of MAFLD on HBV-related stage 0", A hepatocellular carcinoma after curative resection, 2021, pp.11, 684~
68. Semmler G, "Metabolic dysfunction-associated fatty liver disease(MAFLD)-rather a bystander than a driver of mortality", J Clin Endocrinol Metab, 106, pp.2670~2677 (2021)
69. Yun Bin Lee, "Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B", Clinical and Molecular Hepatology, 25(1), pp.52~64 (2019), 대한간학회
70. Tada T, "Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response", Hepatol Res, 51, pp.860~869 (2021)
71. Kenichi Ikejima, "Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights", Clinical and Molecular Hepatology, 26(4), pp.728~735 (2020), 대한간학회
72. Åberg F, "Drinking and obesity : alcoholic liver disease", nonalcoholic fatty liver disease interactions, 2020, pp.40, 154~162
73. Mak LY, "Letter regarding"A new definition for metabolic dysfunction-associated fatty liver disease : an international expert consensus statement"", J Hepatol, 73, pp.1573~1574 (2020)
74. van Kleef LA, "Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B", JHEP Rep, 3, pp.100350~ (2021)
75. Wang MF, "Clinic-pathological features of metabolic associated fatty liver disease with hepatitis B virus infection", World J Gastroenterol, 27, pp.336~344 (2021)
76. Huang Shang-Chin, "Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease", Gut and Liver, 15(3), pp.451~458 (2021), 거트앤리버 소화기연관학회협의회[DOI]
77. Rout G, "Therapy with oral directly acting agents in hepatitis C infection is associated with reduction in fibrosis and increase in hepatic steatosis on transient elastography", J Clin Exp Hepatol, 9, pp.207~214 (2019)
78. Soliman H, "The effect of HCV eradication after direct acting antiviral agents on hepatic steatosis : a prospective observational study", Endocr Metab Immune Disord Drug Targets, 22, pp.100~107 (2022)
79. Ji D, "Nonalcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients : a prospective four-years follow-up study", Metabol Open, 10, pp.100090~ (2021)
80. Yen YH, "The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients", Liver Int, 38, pp.1064~1073 (2018)
81. Peleg N, "Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response", J Viral Hepat, 26, pp.1257~1265 (2019)
82. Fouad Y, "MAFLD considerations as a part of the global hepatitis C elimination effort : an international perspective", Aliment Pharmacol Ther, 53, pp.1080~1089 (2021)
83. Wang Q, "Role of ALDH2 in hepatic disorders : gene polymorphism and disease pathogenesis", J Clin Transl Hepatol, 9, pp.90~98 (2021)
84. Mehta M, "Can alcoholic liver disease and nonalcoholic fatty liver disease coexist?", J Clin Exp Hepatol, 7, pp.121~126 (2017)
85. Senussi NH, "Simultaneous metabolic and alcoholassociated fatty liver disease(SMAFLD)and simultaneous metabolic and alcohol-associated steatohepatitis(SMASH)", Ann Hepatol, 24, pp.100526~ (2021)
86. Khoudari G, "Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort", World J Hepatol, 11, pp.710~718 (2019)
87. Yamamura S, "Profiles of advanced hepatic fibrosis evaluated by FIB-4 index and shear wave elastography in health checkup examinees", Hepatol Res, 50, pp.199~213 (2020)
88. Gentric G, "Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver disease", J Clin Invest, 125, pp.981~992 (2015)
89. Mirra S, "ARMCX3 mediates susceptibility to hepatic tumorigenesis promoted by dietary lipotoxicity", Cancers(Basel), 13, pp.1110~ (2021)
90. Ioannou GN, "Epidemiology and risk-stratification of NAFLD-associated HCC", J Hepatol, 75, pp.1476~1484 (2021)
91. Hwi Young Kim, "Recent advances in nonalcoholic fatty liver disease metabolomics", Clinical and Molecular Hepatology, 27(4), pp.553~559 (2021), 대한간학회[DOI]
92. Eguchi Y, "Hepatocellular carcinoma and other complications of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan : a structured review of published works", Hepatol Res, 51, pp.19~30 (2021)
93. Singal AG, "Epidemiology and surveillance for hepatocellular carcinoma : new trends", J Hepatol, 72, pp.250~261 (2020)
94. Myers S, "NAFLD and MAFLD as emerging causes of HCC : a populational study", JHEP Rep, 3, pp.100231~ (2021)
95. Enomoto H, "The transition in the etiologies of hepatocellular carcinomacomplicated liver cirrhosis in a nationwide survey of Japan", J Gastroenterol, 56, pp.158~167 (2021)
96. Nagaoki Y, "Increasing incidence of non-HBV-and non-HCV-related hepatocellular carcinoma : single-institution 20-year study", BMC Gastroenterol, 21, pp.306~ (2021)
97. David D, "Risk factors for non-alcoholic fatty liver disease are common in patients with non-B non-C hepatocellular carcinoma in India", Indian J Gastroenterol, 36, pp.373~379 (2017)
98. Estes C, "Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030", J Hepatol, 69, pp.896~904 (2018)
99. Mittal S, "Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 14, pp.124~131 (2016)
100. Gawrieh S, "Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis : a United States multicentre study", Aliment Pharmacol Ther, 50, pp.809~821 (2019)
101. Aby E, "Inadequate hepatocellular carcinoma screening in patients with nonalcoholic steatohepatitis cirrhosis", J Clin Gastroenterol, 53, pp.142~146 (2019)
102. Tateishi R, "Hepatocellular carcinoma development in diabetic patients : a nationwide survey in Japan", J Gastroenterol, 56, pp.261~273 (2021)
103. Tokushige K, "Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease", nonalcoholic steatohepatitis 2020, 2021, pp.51, 1013~1025
104. Huang DQ, "Global epidemiology of NAFLD-related HCC : trends, predictions, risk factors and prevention", Nat Rev Gastroenterol Hepatol, 18, pp.223~238 (2021)
105. McGlynn KA, "Epidemiology of hepatocellular carcinoma", Hepatology, 73(Suppl 1(Suppl 1)), pp.4~13 (2021)
106. Singal AG, "Rational HCC screening approaches for patients with NAFLD", J Hepatol, 76, pp.195~201 (2022)
107. Benhammou JN, "Nonalcoholic fatty liver disease risk factors affect liver-related outcomes after direct-acting antiviral treatment for hepatitis C", Dig Dis Sci, 66, pp.2394~2406 (2021)
108. Benhammou JN, "Improved survival after treatments of patients with nonalcoholic fatty liver disease associated hepatocellular carcinoma", Sci Rep, 10, pp.9902~ (2020)
109. Pfister D, "NASH limits anti-tumour surveillance in immunotherapytreated HCC", Nature, 592, pp.450~456 (2021)
110. Eso Y, "Does immune checkpoint inhibitor exhibit limited efficacy against non-viral hepatocellular carcinoma? : a review of clinical trials", Hepatol Res, 52, pp.67~74 (2022)
111. Zurlo F, "Skeletal muscle metabolism is a major determinant of resting energy expenditure", J Clin Invest, 86, pp.1423~1427 (1990)
112. Fan JG, "New trends on obesity and NAFLD in Asia", J Hepatol, 67, pp.862~873 (2017)
113. Chun HS, "Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease", J Cachexia Sarcopenia Muscle, 12, pp.1168~1178 (2021)
114. O’Gorman P, "Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention", Aliment Pharmacol Ther, 52, pp.1387~1398 (2020)
115. Hashida R, "Association between activity and brain-derived neurotrophic factor in patients with non-alcoholic fatty liver disease: a data-mining analysis", Life (Basel), 11, pp.799~ (2021)
116. Hashida R, "Effects of a low-intensity resistance exercise program on serum miR-630, miR-5703, and fractalkine", CX3CL1 expressions in subjects with no exercise habits : a preliminary study, 2021, pp.51, 823~833
117. Gong XF, "MicroRNA-630 inhibits breast cancer progression by directly targeting BMI1", Exp Cell Res, 362, pp.378~385 (2018)
118. Sakurai MA, "Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630", PLoS One, 9, pp.e100124~ (2014)
119. Chen EB, "The miR-561-5p", CX3CL1 signaling axis regulates pulmonary metastasis in hepatocellular carcinoma involving CX3CR1+ natural killer cells infiltration, 2019, pp.9, 4779~4794
120. Yki-Järvinen H, "Dietary carbohydrates and fats in nonalcoholic fatty liver disease", Nat Rev Gastroenterol Hepatol, 18, pp.770~786 (2021)
121. Prenner S, "Moderate exercise for nonalcoholic fatty liver disease", JAMA Intern Med, 176, pp.1083~1084 (2016)
122. Fuster D, "Alcohol use in patients with chronic liver disease", N Engl J Med, 379, pp.1251~1261 (2018)
123. Bosron WF, "Genetic polymorphism of enzymes of alcohol metabolism and susceptibility to alcoholic liver disease", Mol Aspects Med, 10, pp.147~158 (1988)
124. Jong Hwa Choi, "The effect of moderate alcohol drinking in nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 26(4), pp.662~669 (2020), 대한간학회[DOI]
125. Zobair M. Younossi, "A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease", Clinical Gastroenterology and Hepatology, 20(6), pp.e1456~e1468 (2022), Elsevier BV[DOI]
126. Shiha G, "Nomenclature and definition of metabolic-associated fatty liver disease : a consensus from the Middle East and north Africa", Lancet Gastroenterol Hepatol, 6, pp.57~64 (2021)
127. Méndez-Sánchez N, "Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness : Mexican experience", J Hepatol, 75, pp.221~222 (2021)
128. Clayton M, "From NAFLD to MAFLD : nurse and allied health perspective", Liver Int, 41, pp.683~691 (2021)
129. Eslam M, "Defining paediatric metabolic(dysfunction)-associated fatty liver disease : an international expert consensus statement", Lancet Gastroenterol Hepatol, 6, pp.864~873 (2021)
130. Eslam M, "Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases", Lancet Gastroenterol Hepatol, 6, pp.743~753 (2021)
131. Mendez-Sanchez N, "The Latin American Association for the Study of the Liver(ALEH)position statement on the redefinition of fatty liver disease", Lancet Gastroenterol Hepatol, 6, pp.65~72 (2021)
132. Spearman CW, "The sub-Saharan Africa position statement on the redefinition of fatty liver disease : from NAFLD to MAFLD", J Hepatol, 74, pp.1256~1258 (2021)
133. Tan SS, "Endorsing the redefinition of fatty liver disease", Lancet Gastroenterol Hepatol, 6, pp.163~ (2021)
134. Nan Y, "The Chinese society of hepatology position statement on the redefinition of fatty liver disease", J Hepatol, 75, pp.454~461 (2021)

관련 논문AI추천